William Ray

Director, Neurodegeneration Consortium, Institute Head, Neuroscience

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

William Ray is the Director of the Neurodegeneration Consortium and the Institute Head of Neuroscience at The University of Texas MD Anderson Cancer Center in the United States. His research focuses on neurodegenerative diseases, with recent articles addressing topics such as neuroinflammation, chemotherapy-induced peripheral neuropathy, and Alzheimer’s disease mechanisms. Dr. Ray's work includes the discovery of novel molecular classes and inhibitors aimed at advancing treatment approaches for various neurodegenerative conditions.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (4)

Kevin Bieniek

Assistant Professor

University of Texas Health Science Center at San Antonio

UNITED STATES

View details

Wei Cao

Professor

The University of Texas Health Science Center at Houston John P and Katherine G McGovern Medical School

UNITED STATES

View details

Paulino Ramirez

Brown University

UNITED STATES

View details

Wenyan Sun

Assistant Professor

Tulane University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William Ray

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Pathogenic tau–induced transposable element–derived dsRNA drives neuroinflammation

A novel molecular class that recruits HDAC/MECP2 complexes to PU.1 motifs reduces neuroinflammation.

Discovery of IACS-52825, a Potent and Selective DLK Inhibitor for Treatment of Chemotherapy-Induced Peripheral Neuropathy.

Moesin is an effector of tau-induced actin overstabilization, cell cycle activation, and neurotoxicity in Alzheimer's disease.

Pathogenic tau decreases nuclear tension in cultured neurons.

Pathogenic tau accelerates aging-associated activation of transposable elements in the mouse central nervous system

Inhibition of dual leucine zipper kinase prevents chemotherapy-induced peripheral neuropathy and cognitive impairments.

Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia.

First-Time Disclosure of CVN424, a Potent and Selective GPR6 Inverse Agonist for the Treatment of Parkinson's Disease: Discovery, Pharmacological Validation, and Identification of a Clinical Candidate.

Novel Targets for Alzheimer's Disease: A View Beyond Amyloid.

Collaborators (4)

Kevin Bieniek

Wei Cao

Paulino Ramirez

Wenyan Sun

Make your next move.